Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
302 participants
INTERVENTIONAL
2025-11-26
2025-12-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Novel ACT-based Video Game
NCT04566042
Game Intervention for Resilience
NCT07235696
Development and Evaluation of a Psychological Intervention in Videogame Format for the Promotion of Active Aging
NCT04982497
Effects of Temporary Abstinence and Expressive Writing on Gaming
NCT07068035
The Effectiveness of Engagement-based Personalization of a Digital Mental Health Intervention
NCT05300906
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective is to determine whether ACTing Minds yields greater improvement in psychological flexibility and psychological distress than a neutral, engagement-matched game, and whether those process-level changes are accompanied by improvements in wellbeing and related functioning. The trial specifies two co-primary outcomes: psychological flexibility, assessed with the CompACT total score, and general psychological distress, assessed with the DASS-21 total score. For each co-primary outcome, the prespecified primary estimand is the between-group difference in change from baseline to short-term (10-13 days) follow-up. Secondary estimands examine change in CompACT and DASS-21 subscales, subjective wellbeing, social connectedness, health-related quality of life, and autonomic regulation indexed by heart-rate variability derived from short seated ECG recordings.
The study uses a two-arm, parallel-group, randomised design with 1:1 allocation at a single university laboratory site. Randomisation is computer-generated with concealed allocation and implemented after baseline assessment to prevent foreknowledge of assignment. Participants are masked to condition, and blinding integrity is assessed at follow-up by asking participants to guess their allocation. Both arms follow identical procedures and time on task; the comparator is a neutral commercial game selected to match the ACT intervention for duration and engagement while avoiding therapeutic content.
Assessments occur at baseline, immediately after the single session, and 10-13 days post-intervention. Questionnaires are administered electronically with built-in range and completeness checks to minimise entry errors. ECG is recorded seated for about five minutes per timepoint (Lead II). Heart-rate variability processing follows standard steps: signal inspection, identification and correction of artefacts, R-peak verification, derivation of time- and frequency-domain indices, and natural-log transformation of skewed metrics prior to modelling. Mean heart rate (beats per minute) is retained to contextualise autonomic indices.
The statistical analysis plan is specified as follows. Primary and secondary outcomes will be analysed using linear mixed-effects models with fixed effects of Condition, Timepoint and their interaction, and a random intercept for participant to accommodate within-person correlation and incomplete follow-up under maximum likelihood. Residual covariance structures (for example, autoregressive versus unstructured) will be compared using information criteria, retaining the better-fitting specification for each outcome family. The primary contrasts estimate group differences in change from baseline to short-term follow-up on the two co-primary outcomes, CompACT Total and DASS-21 Total; post-session contrasts and 95% confidence intervals will also be reported. Heart-rate variability variables will be analysed on the natural-log scale. Two-sided tests with an alpha of .05 will be used, with attention to confidence intervals and effect sizes. Analyses follow an intention-to-treat principle using all available data; planned sensitivity checks will include alternative covariance structures and, if warranted, supplementary multiple-imputation analyses for outcomes with materially higher missingness.
Data quality procedures include scripted data pipelines with version control, reproducible derivation of analysis datasets from raw sources, and automated checks for ranges, outliers and internal consistency across timepoints. The research team maintains a study data dictionary that defines each variable, coding and scoring rules, and any transformations applied. Access to identifiable data is role-based and restricted to authorised personnel; de-identified analysis files are stored on secure university systems. Adverse events are monitored during the laboratory session and at follow-up, and any serious events are managed according to institutional policy. Given the single-session, minimal-risk behavioural design, an independent data monitoring committee is not required.
The target sample size is approximately 300 participants, providing precise estimates of group differences and allowing robust sensitivity analyses. On completion of the trial and after primary publication, de-identified individual participant data, a data dictionary and analysis code will be shared on a public repository, subject to ethical and legal safeguards. Findings will be disseminated through peer-reviewed publications, conference presentations and lay summaries suitable for non-specialist audiences.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACTing Minds (ACT videogame)
Single \~60-minute session on a study-supplied smartphone in the lab; assessments at baseline, post-session, and short-term follow-up (10-13 days post-intervention).
ACTing Minds (ACT videogame)
Single-session (\~60 min) ACT-based videogame integrating acceptance/openness, cognitive defusion, present-moment awareness, values and values-guided action via structured chapters. Delivered on a study-supplied Samsung Galaxy S9+ (Android) under standardised instructions; no therapist guidance during play.
Neutral commercial puzzle game (Monument Valley)
Engagement- and time-matched \~60-minute smartphone session in the lab; assessments at baseline, post-session, and short-term follow-up (10-13 days post-intervention).
Monument Valley (mobile; neutral control)
Commercial mobile puzzle game used as an engagement- and time-matched control (\~60 min) with no therapeutic content. Delivered on a study-supplied Samsung Galaxy S9+ (Android) in the lab. Title/version fixed for the trial; procedures and environment identical to the experimental arm. No data are collected within the app.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACTing Minds (ACT videogame)
Single-session (\~60 min) ACT-based videogame integrating acceptance/openness, cognitive defusion, present-moment awareness, values and values-guided action via structured chapters. Delivered on a study-supplied Samsung Galaxy S9+ (Android) under standardised instructions; no therapist guidance during play.
Monument Valley (mobile; neutral control)
Commercial mobile puzzle game used as an engagement- and time-matched control (\~60 min) with no therapeutic content. Delivered on a study-supplied Samsung Galaxy S9+ (Android) in the lab. Title/version fixed for the trial; procedures and environment identical to the experimental arm. No data are collected within the app.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to read and understand English
* Self-reported mild to moderate symptoms of depression, anxiety, or stress
* Provides written informed consent
* Willing and able to attend one \~60-minute laboratory session and complete online follow-up questionnaires 10-13 days later
* Agrees to ECG recording (seated \~5 minutes at each timepoint)
* Willing to play either study videogame on a study-supplied Samsung Galaxy S9+ (Android)
Exclusion Criteria
* Current psychotropic medication use (e.g., antidepressants, anxiolytics, antipsychotics, mood stabilisers, stimulants)
* Concurrent psychological therapy (any modality)
* Pregnancy
* Cardiovascular conditions or clinically significant arrhythmias that could affect ECG or HRV measurement or be exacerbated by study procedures
* Implanted cardiac devices (e.g., pacemaker or ICD)
* Any neurological condition, medical condition, or skin condition that would preclude safe ECG electrode placement or comfortable seated recording
* Insufficient English proficiency to provide informed consent or complete study measures
* Any other factor that, in the judgement of the investigators, would compromise safety, data quality, or protocol compliance
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swansea University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Darren Edwards
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darren J Edwards, PhD
Role: PRINCIPAL_INVESTIGATOR
Swansea University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swansea University, School of Psychology (Singleton Park)
Swansea, Wales, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Edwards DJ, Kemp AH. A novel ACT-based video game to support mental health through embedded learning: a mixed-methods feasibility study protocol. BMJ Open. 2020 Nov 16;10(11):e041667. doi: 10.1136/bmjopen-2020-041667.
Gordon TC, Kemp AH, Edwards DJ. Mixed-methods feasibility outcomes for a novel ACT-based video game 'ACTing Minds' to support mental health. BMJ Open. 2024 Mar 29;14(3):e080972. doi: 10.1136/bmjopen-2023-080972.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SU-PSY-ACTM-RCT-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.